Abstract Details

Title Clinical Characteristics and Treatment Response of Patients with Chronic Inflammatory Demyelinating Neuropathy Refractory to Standard Therapy.

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) (-)

Poster/Presentation
Number 093

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Artem Kaplan, MD, PhD (New York Neurology Associates) PRESENTER	No disclosure on file
Thomas Brannagan III, MD, FAAN (Columbia University)	Dr. Brannagan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zenica. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. The institution of Dr. Brannagan has received research support from Alnylam. The institution of Dr. Brannagan has received research support from Abcuro. The institution of Dr. Brannagan has received research support from Ionis. The institution of Dr. Brannagan has received research support from Vertex. The institution of Dr. Brannagan has received research support from NMD Pharma.

��ɫ��